# Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

> **NCT00454818** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celladon Corporation** · enrollment: 51 (actual)

## Conditions studied

- Heart Failure, Congestive
- Dilated Cardiomyopathy

## Interventions

- **GENETIC:** MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
- **PROCEDURE:** Placebo Infusion
- **GENETIC:** MYDICAR Phase 2 (Placebo-controlled, Randomized Study)

## Key facts

- **NCT ID:** NCT00454818
- **Lead sponsor:** Celladon Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-08
- **Final completion:** 2012-08
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454818, "Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00454818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*